Pathological Grading for Predicting Metastasis in Phaeochromocytoma and Paraganglioma
Overview
Oncology
Authors
Affiliations
Phaeochromocytomas (PHEO) and paragangliomas are rare catecholamine-producing tumours. Although 10-30% of these tumours metastasise, histopathological criteria to discriminate malignant from benign tumours have not been established; therefore, reliable histopathological markers predicting metastasis are urgently required. A total of 163 tumours, including 40 metastatic tumours, collected by the Phaeochromocytoma Study Group in Japan (PHEO-J) were analysed using a system called grading system for adrenal phaeochromocytoma and paraganglioma (GAPP). The tumours were scored based on GAPP criteria as follows: histological pattern, cellularity, comedo-type necrosis, capsular/vascular invasion, Ki67 labelling index and catecholamine type. All tumours were scored from 0 to 10 points and were graded as one of the three types: well-differentiated (WD, 0-2 points), moderately differentiated (MD, 3-6 points) and poorly differentiated (PD, 7-10 points). GAPP scores of the non-metastatic and metastatic groups were 2.08±0.17 and 5.33±0.43 (mean±s.e.m., P<0.001) respectively. There was a significant negative correlation between the GAPP score and the interval until metastasis (r=-0.438, P<0.01). The mean number of years until metastasis after the initial operation was 5.5±2.6 years. The study included 111 WD, 35 MD and 17 PD types. The five-year survival of these groups was 100, 66.8 and 22.4% respectively. In addition, negative immunoreactivity for succinate dehydrogenase gene subunit B (SDHB) was observed in 13 (8%) MD or PD tumours and ten of the 13 (77%) had metastases. Our data indicate that a combination of GAPP classification and SDHB immunohistochemistry might be useful for the prediction of metastasis in these tumours.
Edamadaka Y, Bal M, Rane S, Parghane R, Basu S World J Nucl Med. 2025; 24(1):83-92.
PMID: 39959153 PMC: 11828642. DOI: 10.1055/s-0044-1791819.
Nakabayashi H, Akiyama M, Yodokawa T, Itoh W, Taguchi A, Takeda K Cureus. 2025; 17(1):e77459.
PMID: 39958118 PMC: 11828756. DOI: 10.7759/cureus.77459.
Prognosis and tumor microenvironment in pseudohypoxic pheochromocytoma/paraganglioma.
Ohmoto A, Shigematsu Y, Saito R, Dobashi A, Fujiwara Y, Togashi Y Virchows Arch. 2024; .
PMID: 39694932 DOI: 10.1007/s00428-024-04009-x.
Ishizaki F, Taguchi T, Murata M, Hoshino S, Toba T, Takeda K Sci Rep. 2024; 14(1):26456.
PMID: 39488586 PMC: 11531473. DOI: 10.1038/s41598-024-75354-9.
de Bresser C, de Krijger R Endocr Pathol. 2024; 35(4):279-292.
PMID: 39466488 PMC: 11659362. DOI: 10.1007/s12022-024-09830-3.